Antibody targeting the PSGL-1 N-terminus (Fig. 9D) or sLex and recombinant OmpA19–74 that competitively antagonizes A. phagocytophilum access to sLex strongly inhibits both bacterial binding and infection (5, 7, 9). This evidence concerns the gene SELPLG and infection.